« FDA To Get Tough On Outsourced Drugmaking | Main | Lilly CEO "innovation crisis in America's life-sciences sector" »

06/18/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b013484a01961970c

Listed below are links to weblogs that reference Genzyme: The Rest of the Story:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

thePharmaletter reports EMEA has recommended Replagel as an alternative Fabry treatment to GZ's fabrazyme in wake of shortages
http://www.thepharmaletter.com/file/96470/emea-recommends-replagal-as-alternative-fabry-treatment-due-to-fabrazyme-shortage-fda-approves-shires-daytrana-for-adolescents.html

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada